Goldman Sachs downgraded Avantor (AVTR) to Neutral from Buy with a price target of $14, down from $23. The firm says it wrongly assumed that Avantor’s “aggressive” cost savings program and a bioprocessing business in recovery mode would be enough to continue to drive increased margin expansion and growth. Goldman is now concerned the company’s Laboratory Solutions business will continue to be a drag on overall growth as competitive pressures intensify and macro headwinds persist.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTR:
- Avantor price target lowered to $20 from $24 at RBC Capital
- Avantor Announces Leadership Transition with CEO Departure
- Avantor price target lowered to $16 from $24 at Raymond James
- Avantor’s Stock: Buy Rating Amidst Challenges and Strategic Initiatives
- Avantor price target lowered to $17 from $21 at Baird